RXST
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a low multiple of book value, but lacks earnings to support a traditional valuation.
- Low Price/Book (1.14)
- Reasonable Price/Sales (2.34)
- Negative earnings preclude Graham Number calculation
- Forward P/E is negative
Future outlook is clouded by shrinking revenues despite cost-cutting or efficiency gains in EPS.
- EPS is trending upward
- Analyst target price ($9.93) suggests upside
- Revenue growth is negative (-18.9%)
- Operating margins remain deeply negative
Long-term historical performance is overwhelmingly negative.
- Consistent earnings surprises
- 1Y return of -47.3%
- 5Y return of -52.4%
The company is solvent and liquid, but the F-Score indicates a collapse in operational efficiency and financial strength.
- Extremely low Debt/Equity
- High Quick Ratio (9.58)
- Piotroski F-Score of 1/9 is a major red flag
Non-dividend paying growth/speculative stock.
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for RXST and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
RXST
RxSight, Inc.
Primary
|
-52.4% | -56.2% | -47.3% | -7.7% | +3.5% | +11.4% |
|
CV
CapsoVision, Inc.
Peer
|
+79.0% | +79.0% | +79.0% | +33.0% | +22.8% | -14.1% |
|
AMRN
Amarin Corporation plc
Peer
|
-88.3% | -51.5% | +87.1% | +2.2% | +1.5% | +9.1% |
|
ACIU
AC Immune SA
Peer
|
-62.7% | +31.1% | +31.1% | +24.1% | -0.5% | +8.1% |
|
PRE
Prenetics Global Limited
Peer
|
-84.7% | +41.9% | +344.6% | +18.9% | -12.8% | +0.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
RXST
RxSight, Inc.
|
BEARISH | $314.04M | - | -14.0% | -29.0% | $7.61 | |
|
CV
CapsoVision, Inc.
|
BEARISH | $312.24M | - | -184.9% | -186.8% | $6.26 | Compare |
|
AMRN
Amarin Corporation plc
|
BEARISH | $319.13M | - | -8.2% | -18.2% | $15.34 | Compare |
|
ACIU
AC Immune SA
|
BEARISH | $303.31M | - | -74.6% | -% | $3.02 | Compare |
|
PRE
Prenetics Global Limited
|
NEUTRAL | $300.86M | - | -31.8% | -63.1% | $17.83 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | GAINES SCOTT | Officer | Stock Award | 6,261 | - |
| 2026-02-27 | WILTERDING MARK | Chief Financial Officer | Stock Award | 20,441 | - |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning RXST from our newsroom.